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Abstract
Background: Contovir is a mixture of herbal extracts (Tanacetum vulgare, Rossa canina, Urtica dioica) that is supplemented with
selenium.
Objectives: This study aimed to add Contovir to the classic treatment of recurrent respiratory papillomatosis (RRP) in order to
decrease the severity and extent of the disease, elongate the surgical intervals and improve the sense of patient well-being. Further-
more, we had to adjust the prescribed drug dosage, since there were no previous findings available.
Patients and Methods: This is a case study of RRP patients treated with Contovir as an adjuvant to the classic treatment, from
March 2011 to February 2013, at an academic tertiary hospital (Rasoul-e-Akram hospital). All patients underwent surgical removal of
papilloma and then were prescribed Contovir. Disease severity was quantified based on Derkay’s staging system.
Results: Eight patients were enrolled in this study. The extent and severity of the disease improved in six cases. One had no response,
and the severity of disease increased in one patient. Patients with supraglottic lesions had better responses to Contovir adjuvant
therapy. No immediate or long-term side effects were reported.
Conclusions: Although Contovir has been found to be an advantageous adjuvant for RRP treatment, further studies are called for
to verify these findings.
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1. Background
Recurrent respiratory papillomatosis (RRP) is a recur-
rent benign tumor of the respiratory tract. It is caused
by genital tract human papillomaviruses (type 6 and 11
are the most common causes). This disease is transmit-
ted during normal vaginal delivery from the infected birth
canal to the respiratory tract of the child (1). The incidence
of RRP in children is 1 - 4 per 100,000 and among adults
is 1.8 - 3.9 per 100,000 (2). The major treatment modal-
ity for RRP is surgical de-bulking of papilloma by means
of laser ablation or microdebridment. RRP does not cure
the disease, due to papilloma regrowth after surgical re-
moval. Studies have shown that approximately 4.4 pro-
cedures per year are needed for each patient with severe
RRP (3). The frequent surgery requirement brings emo-
tional and economic burdens on the patients and their
families. Accordingly, laryngologists attempt to reduce
the frequency of procedures by using non-invasive modali-
ties including supplementation with an antiviral adjuvant.
The criterion for adjuvant therapy is the need for surgery
more than four times per year (4). Clinical trials have
shown some controlling effect of adjuvants such as inter-
feron alfa, cidofovir, indole-3-carbinol, acyclovir, ribavirin,
isotretinoin, methotrexate, the mumps vaccine, and pho-
todynamic therapy on RRP treatment. Interferon alfa and
cidofovir have antiviral activities, and they also modulate
the host immune response to HPV (4). Contovir, as a new
version of an IMOD (immuno-modulatory drug), is a mix-
ture of herbal extracts (Tanacetum vulgare, Rossa canina,
Urtica dioica) supplemented with selenium, carotene and
flavonoids (5, 6). The anti-inflammatory and antioxida-
tive effects of IMODs have been shown on colitis, type 1
diabetes, pancreatic Langerhans islet transplantation and
polycystic ovary syndrome. Previous studies showed the
immunostimulation and antiviral effect of IMODs in HIV-
infected patients (7, 8). Safety and potential mutagenic and
genotoxic studies in the preclinical and clinical phase have
demonstrated that IMODs are safe and non-mutagenic (6).
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2. Objectives
Based on the requirement for a new, safe and cost-
effective adjuvant, this study evaluates Contovir as a sup-
plement to the classic treatment of RRP.
3. Patients and Methods
3.1. Methods
This is a case study regarding patients with RRP, which
were enrolled in a prospective follow-up using Contovir
for the treatment of RRP from March 2011 to February 2013
in Rasoul-e-Akram hospital; a tertiary referral hospital in
Tehran, Iran affiliated with Iran University of Medical Sci-
ences. Prior to beginning the treatment with Contovir, pa-
tients underwent endoscopic evaluation in the operating
room to locate and quantify the extent of the disease. The
rate of recurrence was determined by reviewing the last 12
months of surgical history. To standardize the treatment,
the surgeon discontinued all other adjuvant therapies in-
cluding I3C and INF.
Disease severity was quantified based on the staging
system described by Derkay et al. (9) The initial dose of Con-
tovir was 1.5 mg/kg IV. Since it causes phlebitis in children,
it was administered orally. Contovir dosing was continued
as: 3 mg/kg, 6 mg/kg (10th study month), 20 g/kg (16th study
month).
3.2. Patients
Pretreatment laboratory tests were performed on all
patients, including CBC diff, FBS, BUN, Cr, Na, K, liver func-
tion tests, and urinalysis. These tests were repeated before
each surgery. Patients, or their parents, consented to the
drug administration. In each surgery, the patient’s voice
and airway condition was documented. Patients were also
asked about experienced side effects.
This study was approved by the institutional review
board of Tehran University of Medical Sciences ethics com-
mittee. Written informed consent was obtained from the
patients, and the study protocol conformed to the ethical
guidelines of the 1975 declaration of Helsinki, as reflected
in a prior approval by the institution’s human research de-
partment.
4. Results
To evaluate the efficacy of Contovir in the treatment of
RRP, nine patients were enrolled in this study. One patient
dropped out during follow-up, due to noncompliance with
the medication.
Demographic data for the patients are shown in Table
1. Average age at initial treatment of RRP was 3.6 years.
Patients were between 2 and 56 years old. Seven patients
were≤ 15 years old. Case 1 had glottic stenosis secondary to
malpractice and multiple surgeries for RRP in another cen-
ter. Due to this patient’s weak responses to surgery and the
medication used in this trial, we had to administer INF and
I3C, and after all four surgeries, his Derkay’s scores were not
changed.
This study included six patients who responded to Con-
tovir as adjuvant therapy. The score remained constant for
one patient (case 3) and was increased for another (case 1).
The response appeared after the second surgery on
Contovir (P = 0.042) and two patients showed more signif-
icant response to Contovir (cases two and six).
In cases two and eight papilloma disappeared in the
supraglottis, and in cases four and seven the lesion’s exten-
sion decreased in the supraglottis. This change was more
visible after the second surgery on Contovir. In addition,
the glottic lesions responded on the third surgery.
Tracheal and subglottic papilloma did not respond to
Contovir, demonstrating that only two of five patients with
tracheal involvement had a decreasing tracheal score.
5. Discussion
Numerous studies have been designed to evaluate the
role of different adjuvants for improvement of the course
of RRP. Interferon alfa is the most common adjuvant ther-
apy for RRP. In one study of 60 RRP patients, Leventhal et al.
reported a 78% response rate to interferon (10). Rosen et al.
showed, in a study of 21 RRP patients treated with indole-
3-carbinol, a complete response in 33%, a partial response
in 30% and no response in 37% of patients (11). In a review
of the intra lesional effect of cidofovir on RRP patients by
Chadha et al., patients demonstrated 57% complete resolu-
tion, 35% partial response and 8% no improvement (12).
Despite the positive responses to these medications,
their adverse effects are mentioned. Neuropsychiatric
complications and bone marrow suppression are two ma-
jor complications of interferon. One of its limitations is a
rebound phenomenon after a primary positive response
(4). In addition, intravenous cidofovir has nephrotoxic
side effects and it is potentially carcinogenic in animals
(12).
In our study, six of eight patients responded to Con-
tovir. It is not understood why some patients experienced
near complete remission of papilloma, whereas others had
partial responses or none at all. HPV11 and tracheal lesions
are two predictors of severe RRP (13). Case 1 had laryngeal
comorbidity, and this patient’s HPV type was HPV11. Case 3
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had only tracheal involvement. These are important char-
acteristics to define the lack of response to Contovir. It is
important to note that the response to Contovir was rapid
and occurred after the second surgery.
Both cases 2 and 6, who had good responses, had four
surgeries in the last year . These cases showed a decrease in
disease scores on the supraglottis and glottis. They were
followed for one year, and their score did not increase.
Supraglottic and glottic lesions showed better and more
significant responses compared to subglottic and tracheal
papilloma. No adverse effect (clinical and laboratory) was
detected in this study.
There are no previous studies of Contovir administra-
tion for treatment of RRP. Our findings provide beneficial
evidence of Contovir as an adjuvant for RRP treatment that
is efficacious, well-tolerated and a noninvasive oral drug.
The limitations of the present study include lack of a con-
trol group, unknown HPV typing and short-term follow-up.
Therefore, additional studies are recommended.
5.1. Conclusion
Our results show that Contovir can be a safe and ef-
fective adjuvant therapy for patients with RRP, but further
clinical trials are necessary before it can be recommended
for widespread use.
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Table 1. The patients’ Scores at Initiation and After Contovir Treatment, the Subunits Score and the Extension and Severity of Papilloma
Subunits Pre Contovir Score 1th OP on Contovir 2th 3th 4th 5th 6th 7th
Patient number =1; Gender = male; Age, y = 2; Age (First presentation), y = 0.5; Total Number of Opertion in Last Year = 5; Comorbidity = Glottic stenosis; Tracheotomy = +
Supra glottis 22 21 6 21 12 24 6 21
Glottis 12 12 9 12 12 12 12 12
Sub glottis 3 3 3 3 3 3 3 3
Trachea 6 9 6 6 3 9 9 9
Total 43 45 24 42 30 48,
(INF+I3C)
6
3020 45
Patient number =2; Gender = male; Age, y = 4; Age (First presentation), y = 1.5; Total Number of Opertion in Last Year = 4; Comorbidity = None; Tracheotomy = +
Supra glottis 4 0 0 0
Glottis 1 0 0 0
Sub glottis 3 0 0 0
Trachea 6 9 4 2
Total 14 9 4 2a
Patient number = 3; Gender = female; Age, y = 15; Age (First presentation), y = 5; Total Number of Opertion in Last Year = 4; Comorbidity = None; Tracheotomy = +
Supra glottis 0 0 0 0
Glottis 0 0 0 0
Sub glottis 0 0 0 0
Trachea 6 9 9 6
Total 6 9 9 66
Patient number = 4; Gender = male; Age, y = 11; Age (First presentation), y = 1; Total Number of Opertion in Last Year = 3; Comorbidity = None; Tracheotomy = -
Supra glottis 6 3 6 1 3 6 3
Glottis 5 7 6 2 9 6 4
Sub glottis 0 0 1 0 1 3 0
Trachea 3 0 0 0 0 0 0
Total 14 10 13 3 13 15 7
Patient number = 5; Gender = male; Age, y = 56; Age (First presentation), y = 3; Total Number of Opertion in Last Year = 1; Comorbidity = None; Tracheotomy = -
Supra glottis 0 3 3 0 0
Glottis 6 3 3 1 0
Sub glottis 3 3 3 3 3
Trachea 6 3 3 6 9
Total 15 12 12 10 12
Patient number = 6; Gender = female; Age, y = 15; Age (First presentation), y = 13; Total Number of Opertion in Last Year = 4; Comorbidity = None; Tracheotomy = -
Supra glottis 0 1 0
Glottis 9 2 1
Sub glottis 0 0 0
Trachea 0 0 0
Total 9 3 1
Patient number = 7; Gender = female; Age, y = 3.5; Age (First presentation), y = 3.5; Total Number of Opertion in Last Year = 0; Comorbidity = GE reflux; Tracheotomy = -
Supra glottis 6 6 0 2 2 0 0
Glottis 9 9 9 5 9 9 6
Sub glottis 0 0 0 0 0 0 0
Trachea 0 0 0 0 0 0 0
Total 15 15 9 7 11 9 6
Patient number = 8; Gender = female; Age, y = 9; Age (First presentation), y = 4; Total Number of Opertion in Last Year = 0; Comorbidity = None; Tracheotomy = -
Supra glottis 3 0 0 1
Glottis 9 9 9 8
Sub glottis 0 0 0 0
Trachea 0 0 0 0
Total 12 9 9 9
a During one year follow up, any lesion didn’t see in laryngoscopy.
4 Iran Red Crescent Med J. 2017; 19(12):e21577.
